Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

NCT04352777 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Locally Advanced Breast Cancer
Hormone Receptor Positive Tumor

Interventions

DRUG: Abemaciclib
DRUG: Fulvestrant
DRUG: Aromatase Inhibitors

Sponsor

Duke University